Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Feb 10.

Published in final edited form as: Nat Med. 2011 Jun 19;17(7):854–859. doi: 10.1038/nm.2390

a. The IEEL contained cDNA from three TCR2 tumors cloned into VSV. b. Western blot for murine N-Cadherin from BHK cells infected with VSV (1), IEEL Reverse (2) or Direct (3) (MOI ~10). Equal loading confirmed by ß-actin probing. c. Survival of mock, or VSV-GFP,-vaccinated mice bearing 7d TC2 tumors treated with three i.v. injections of VSV-GFP or ASEL, either as viral supernatant (10⁷pfu) or as virus pre-loaded onto CD8+ T cells [T(ASEL)]. d. Mice bearing 7d TC2 tumors were treated i.v. with VSV-GFP or ASEL (days 7,9,11). On days 25,27,29 mice initially treated with ASEL received i.v. IEEL virus pre-loaded onto CD8+ T cells [T(IEEL)]. e. VSV-vaccinated mice bearing 7d TC2 tumors were injected intravenously with VSV-GFP, ASEL or IEEL (10⁷pfu) or with virus pre-loaded onto CD8+ T cells [T(ASEL)/T(IEEL)] (d 7,9,11). On days 20,22,24, surviving mice were treated i.v. with T cells loaded with IEEL [T(ASEL)/T(IEEL)] or ASEL [T(ASEL)/T(ASEL)]. f-i. Splenocytes from mice which either did (f,g) or did not (h,i) reject TC2/TC2R tumors following i.v. ASEL + T(IEEL) (d) or T(ASEL) + T(IEEL) (e) were co-cultured with lysates of TC2, TC2R, B16, normal mouse prostate or pancreas and assayed for (f,g) IL-17 or (h,i) IFN-γ. Results are from three survivor mice (f,g) or two mice which succumbed to TC2R tumors (h,i).

a. The IEEL contained cDNA from three TCR2 tumors cloned into VSV. b. Western blot for murine N-Cadherin from BHK cells infected with VSV (1), IEEL Reverse (2) or Direct (3) (MOI ~10). Equal loading confirmed by ß-actin probing. c. Survival of mock, or VSV-GFP,-vaccinated mice bearing 7d TC2 tumors treated with three i.v. injections of VSV-GFP or ASEL, either as viral supernatant (10⁷pfu) or as virus pre-loaded onto CD8+ T cells [T(ASEL)]. d. Mice bearing 7d TC2 tumors were treated i.v. with VSV-GFP or ASEL (days 7,9,11). On days 25,27,29 mice initially treated with ASEL received i.v. IEEL virus pre-loaded onto CD8+ T cells [T(IEEL)]. e. VSV-vaccinated mice bearing 7d TC2 tumors were injected intravenously with VSV-GFP, ASEL or IEEL (10⁷pfu) or with virus pre-loaded onto CD8+ T cells [T(ASEL)/T(IEEL)] (d 7,9,11). On days 20,22,24, surviving mice were treated i.v. with T cells loaded with IEEL [T(ASEL)/T(IEEL)] or ASEL [T(ASEL)/T(ASEL)]. f-i. Splenocytes from mice which either did (f,g) or did not (h,i) reject TC2/TC2R tumors following i.v. ASEL + T(IEEL) (d) or T(ASEL) + T(IEEL) (e) were co-cultured with lysates of TC2, TC2R, B16, normal mouse prostate or pancreas and assayed for (f,g) IL-17 or (h,i) IFN-γ. Results are from three survivor mice (f,g) or two mice which succumbed to TC2R tumors (h,i).